Methodological insights into fecal microbiota transplantation: Dissecting key approaches for success

Table 6 Fecal microbiota transplantation: Current uses and future horizons

Established indication
Clostridioides difficile infection[7,11-14,48]
Investigational/emerging indications
Ulcerative colitis[45,49]	Primary sclerosing cholangitis[62,63]
Crohn’s Disease[47,50]	Intestinal pseudoobstruction[64]
Pouchitis[51]	Neurodegenerative disorders (Alzheimer’s disease, Parkinson’s disease, multiple sclerosis)[65]
Irritable Bowel Syndrome[52]	Graft vs host disease[66]
Alcoholic hepatitis[53]	Human immunodeficiency virus[67]
Cirrhosis or hepatic encephalopathy[54]	Methicillin-resistant Staphylococcus aureus enterocolitis[68]
Obesity/metabolic syndrome[55]	Multidrug-resistant organisms[69]
Diabetes mellitus[56]	Post-stem cell transplant[70]
NAFLD/NASH[57]	Autologous FMT (preventive)[71,72]
Hepatitis B[58,59]	Autism spectrum disorders[73]
Pancreatitis[60]	Cancer[74]
Immune checkpoint inhibitor resistance[61]	Fecal incontinence[75]

FMT: Fecal microbiota transplantation; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.